FarmavitaR+

1. Advances in Imaging Biomarkers
(Reports/Market Report)

Innovative technologies, applications in R&D and clinical practice, and informatics and regulatory requirements This report discusses advances in key technologies, the use of imaging biomarkers ...

2. Pricing and Reimbursement Strategies
(Reports/Market Report)

Pricing and Reimbursement Strategies for Diagnostics: Overcoming reimbursement issues and navigating the regulatory environment The reimbursement for diagnostics is the key requirement for both the ...

3. Clinical Trials 2010
(Events/Events)

... in western countries • The effect of EU regulations on conducting clinical trials- work with regulatory authorities   Come to learn and explore continuing and emerging opportunities and issues in ...

4. How to run the right clinical trials?
(Events/Events)

... in the regulatory & legal environment • Best practices in designing a study protocol Event info: T:+421 257 272 110         F: +421 255 644 490 E: events@jacobfleming.com  ...

5. Ukraine in prospect of joining PIC/S
(Regulatory Affairs/Europe not-EU)

... Ministry of Ukraine, Chief State Inspector of Ukraine for Quality Control of Drugs. Pharmaceutical Inspection Cooperation System - PIC / S - an international agreement between national regulatory authorities ...

6. Drug Repositioning & R&D Enhancement
(Events/Events)

... to benchmark best practices with their industry peers in order to develop sound strategies for drug repositioning.  Key conference topics: Grasp the most recent regulatory requirements for Review ...

7. Evolution Summit 2010
(Business News/Press Release)

... encounter in their day to day practice is the variety of countries that they deal with and the different regulatory issues that they need to solve. If you have a multi-center multi-national trial in ...

8. eCTD
(Events/Events)

... the 14th and 15th of September 2010. With eCTD submissions taken a firm hold in the US and Japan, they are now making their mark in Europe. Now eCTD submissions are becoming the preferred format for regulatory ...

9. Fibromyalgia
(Regulatory Affairs/Regulatory Affairs News)

Fibromyalgia - Regulatory caution threatens EU market expansion Until regulatory hurdles in the EU are overcome, the US offers the greatest commercial potential and will be the primary growth market ...

10. Introduction of Braille script for pharmaceuticals in Ukraine
(Regulatory Affairs/Europe not-EU)

20.05.2009 was introduced an amendment to the law of Ukraine “On medicines” (№ 124/96ВР of 4.04.96) which orders to use Braille script on packages. Changes came into force until 01.01.10. In Ukraine ...

11. Patern Ltd.
(Partners/Regulatory Affairs)

... System by TÜV Rheinland Group at 23 of December 2009. And today we are the ISO-certified company, a reliable partner for you at Ukrainian pharmaceutical market. Main services of company: · Regulatory ...

12. Regulatory Updates - Free Webinar Series
(Regulatory Affairs/North America)

Free Webinar Series In order to fulfill dicentra’s mission to serve the natural health products industry as a source for education and trusted scientific and regulatory information, we offer free quarterly ...

13. Patern Ltd.
(Partners/Regulatory Affairs)

... ISO 9001:2008 standards. Regulatory affairs, registration, renewal and variation of original and generic products, in-bulk, medical devices, nutritional supplements and healthcare cosmetic; Clinical ...

14. Emerging Biosimilars Landscape
(Reports/Market Report)

Biosimilars: Key developments in the regulatory environment This report examines the structure of the biopharmaceutical industry and the strategic approaches taken to alleviate the threat posed by the ...

15. Emerging Clinical Trial Locations
(Clinical Trilas/Europe not-EU)

Emerging Clinical Trial Locations: Market dynamics and the changing healthcare and regulatory environment This report provides a comprehensive examination of the clinical trial landscape in emerging ...

16. Key Trends In Drug-diagnostic Co-development
(Reports/Market Report)

Key Trends In Drug-diagnostic Co-development: Identifying collaborative opportunities and navigating regulatory challenges This report explores the potential for applying genomic-based diagnostics to ...

17. Biosimilars: Key developments in the regulatory environment
(Reports/Product Report)

Negotiating the Emerging Biosimilars Landscape: Key developments in the regulatory environment As regulatory obstacles to biosimilars development have become increasingly resolved, a growing number of ...

18. Croatia - Pricing and Reimbursement News
(Pricing and Reimbursment/Pricing and Reimbursment)

... and reimbursement list. FarmavitaR+ is part of global network of regulatory affairs consultants. Please contact us related to your international regulatory affairs projects.  ...

19. Biosimilars expansion in the USA
(Biosimilars/Biosmimilars)

... the Emerging Biosimilars Landscape: Key developments in the regulatory environment priced $3,835 RBHC0216 Generic Benchmarking: Brand Erosion at Patent Expiry priced $7,600 DMHC2496  ...

20. Drug repositioning
(Regulatory Affairs/Other issues)

...  Although drug repositioning offers considerable advantages over conventional drug discovery, the regulatory and intellectual property issues associated with it require special attention. Most leading ...